Cargando…

Sars-Cov-2 and risk of antiviral drug resistance

Detalles Bibliográficos
Autor principal:	Vitiello, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554178/ https://www.ncbi.nlm.nih.gov/pubmed/34714491 http://dx.doi.org/10.1007/s11845-021-02820-y

Ejemplares similares

Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants
por: Bojkova, Denisa, et al.
Publicado: (2022)

Aminoglycosides and their potential as SARS-CoV-2 antivirals
por: Cimolai, Nevio
Publicado: (2021)

SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain
por: Lens, Sabela, et al.
Publicado: (2020)

Boron enhances the antiviral activity of the curcumin against SARS-CoV-2
por: Scorei, Ion Romulus, et al.
Publicado: (2020)

Inferring SARS-CoV-2 functional genomics from viral transcriptome with identification of potential antiviral drugs and therapeutic targets
por: Pan, Xu, et al.
Publicado: (2021)

5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro
por: Ngwe Tun, Mya Myat, et al.
Publicado: (2022)

The differential roles of zinc in immune responses and their potential implications in antiviral immunity against SARS-CoV-2
por: Reinhold, Dirk, et al.
Publicado: (2021)

Potential resistance to SARS-CoV-2 infection in lysosomal storage disorders
por: Pieroni, Maurizio, et al.
Publicado: (2021)

Antiviral Drugs for Viral Pneumonia
por: Bansal, Tapesh
Publicado: (2023)

Drug induced hepatitis and SARS-CoV-2 vaccination: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

New emerging SARS-CoV-2 variants and antiviral agents
por: Vitiello, A., et al.
Publicado: (2023)

RNASeq profiling of COVID19‐infected patients identified an EIF2AK2 inhibitor as a potent SARS‐CoV‐2 antiviral
por: Jain, Sidharth, et al.
Publicado: (2022)

SARS-CoV-2 and dentistry
por: Ortega, Karem L., et al.
Publicado: (2020)

Immune response in SARS-CoV-2
por: Aguilar-Shea, Antonio Luis, et al.
Publicado: (2020)

Letter to the editor: Anti-RAS drugs and SARS-CoV-2 infection
por: Bian, Jingwei, et al.
Publicado: (2020)

Drug-induced hepatitis (DIH) after SARS-CoV-2 vaccination
por: Asgarzdeh, Ali, et al.
Publicado: (2023)

Is SARS-CoV-2 an oncogenic virus?
por: Gómez-Carballa, Alberto, et al.
Publicado: (2022)

Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection
por: Tang, Mi, et al.
Publicado: (2021)

Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection
por: Tang, Mi, et al.
Publicado: (2021)

Protections against the Risk of Airborne SARS-CoV-2 Infection
por: McDonald, Clement J.
Publicado: (2020)

No arguments for extra risk from ibuprofen in SARS-COV2 infection
por: Moore, Nicholas
Publicado: (2020)

SARS-CoV-2 vaccination and thrombotic risk in myeloproliferative neoplasms
por: Borsani, Oscar, et al.
Publicado: (2023)

Drug-drug interaction with oral antivirals for the early treatment of COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2023)

Don't worry! The next generation would be more resistant to SARS-CoV-2
por: Bevelacqua, Joseph J., et al.
Publicado: (2020)

Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab
por: Vellas, Camille, et al.
Publicado: (2022)

Detection of SARS-CoV-2 by Use of the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 Assays
por: Moran, Angelica, et al.
Publicado: (2020)

Computational repurposing of asthma drugs as potential inhibitors of SARS-CoV-2 M(pro)
por: Hussain, A., et al.
Publicado: (2022)

Risk factors for SARS-CoV-2 transmission in non-household clusters
por: Noh, Ji Yun, et al.
Publicado: (2021)

Clinical Manifestation and the Risk of Exposure to SARS-CoV-2 (COVID-19)
por: Aleebrahim-Dehkordi, Elahe, et al.
Publicado: (2020)

Concerns regarding risk factors for SARS-CoV-2 transmission to pets
por: Weese, Scott
Publicado: (2023)

The dynamics of antibodies to SARS-CoV-2 in a case of SARS-CoV-2 infection
por: Xia, Yong, et al.
Publicado: (2020)

Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment
por: Vellas, Camille, et al.
Publicado: (2022)

Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir?
por: Clark, Nicole F., et al.
Publicado: (2022)

Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?
por: Vitiello, Antonio, et al.
Publicado: (2021)

SARS-CoV-2 in cardiomyocytes
por: Finsterer, Josef
Publicado: (2021)

Pharmacotherapeutics of SARS-CoV-2
por: Gupta, Harish, et al.
Publicado: (2022)

Overinterpretation of the antiviral results for human coronavirus strain 229E (HCoV‐229E) relative to severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)
por: Shewale, Jaiprakash G., et al.
Publicado: (2021)

SARS-CoV-2 infection in aplastic anemia
por: Avenoso, Daniele, et al.
Publicado: (2021)

Reply to “Intensification of an Essential Tremor by SARS-CoV-2”
por: Passaretti, Massimiliano, et al.
Publicado: (2022)

SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_90fghelvjaat6omau9m5kud9bb